Objective. To evaluate the clinical and laboratory course of the COVID-19 patients who received antiviral treatment with remdesivir.

Materials and methods. The study included 191 hospitalized patients (106 men (55.5 %) and 85 women (44.5 %); the median age of patients in the study was 54.0 [42.0; 62.0] years) with COVID-19 in Minsk City Clinical Hospital of Infectious Diseases, Minsk 2nd City Clinical Hospital, Mogilev Infectious Diseases Hospital, Mogilev Hospital No. 1. The inclusion criterion of the study was the administration of remdesivir. Basic patients’ characteristics, frequency of admission to intensive care and resuscitation units, outcomes of hospitalization, changes in complete blood count, biochemical analysis, and coagulation were evaluated on different days of remdesivir treatment.

Results. The frequency of admission to intensive and resuscitation units was 41 (21.5 %). The overall mortality rate among the patients included in the study was 27 (14.1 %). Statistically significant differences in median age were revealed depending on the outcome of hospitalization: 63.0 [55.0; 68.5] years and 51.0 [40.3; 60.0] year for the deceased and discharged respectively (p <0.001). In patients with lethal outcome an increase in the level of leukocytes was revealed (14.3 [11.1; 15,4]×109/l) due to segmented neutrophils (10.8 [7.9; 12.5]×109/l), lactate dehydrogenase (1093.0 [738.4; 1974.9] U/l), and consistently high level of C-reactive protein (26.3 [11.5; 49.7] mg/l) on day 6 from remdesivir administration.

Conclusion. Patients with a lethal outcome were characterized by an older age, changes in clinical and laboratory parameters that did not exclude bacterial complications. An increase in leukocytes due to neutrophils together with persistent lymphopenia, high level of C-reactive protein, increasing